GB0324763D0 - Use of compounds in therapy - Google Patents

Use of compounds in therapy

Info

Publication number
GB0324763D0
GB0324763D0 GBGB0324763.2A GB0324763A GB0324763D0 GB 0324763 D0 GB0324763 D0 GB 0324763D0 GB 0324763 A GB0324763 A GB 0324763A GB 0324763 D0 GB0324763 D0 GB 0324763D0
Authority
GB
United Kingdom
Prior art keywords
alkyl
cor
hydrogen
independently hydrogen
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0324763.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxagen Ltd
Original Assignee
Oxagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxagen Ltd filed Critical Oxagen Ltd
Priority to GBGB0324763.2A priority Critical patent/GB0324763D0/en
Publication of GB0324763D0 publication Critical patent/GB0324763D0/en
Priority to EP09002934A priority patent/EP2060258A1/en
Priority to PT04768943T priority patent/PT1682121E/pt
Priority to HK07100163.4A priority patent/HK1093435B/en
Priority to JP2006536158A priority patent/JP4313819B2/ja
Priority to PCT/GB2004/004417 priority patent/WO2005044260A1/en
Priority to KR1020067007822A priority patent/KR20060096145A/ko
Priority to CN2004800311128A priority patent/CN101141956B/zh
Priority to DK04768943T priority patent/DK1682121T3/da
Priority to UAA200605567A priority patent/UA86602C2/ru
Priority to DE602004022579T priority patent/DE602004022579D1/de
Priority to ES04768943T priority patent/ES2330113T3/es
Priority to SI200431276T priority patent/SI1682121T1/sl
Priority to EP04768943A priority patent/EP1682121B1/en
Priority to HR20090577T priority patent/HRP20090577T8/xx
Priority to AT04768943T priority patent/ATE439129T1/de
Priority to AU2004287245A priority patent/AU2004287245B2/en
Priority to BRPI0415374A priority patent/BRPI0415374B8/pt
Priority to CA2543199A priority patent/CA2543199C/en
Priority to NZ547319A priority patent/NZ547319A/en
Priority to PL04768943T priority patent/PL1682121T3/pl
Priority to RU2006109769/04A priority patent/RU2412934C2/ru
Priority to US10/972,060 priority patent/US7582672B2/en
Priority to NO20061456A priority patent/NO335228B1/no
Priority to IL175085A priority patent/IL175085A0/en
Priority to ZA200603235A priority patent/ZA200603235B/xx
Priority to US12/232,444 priority patent/US8163931B2/en
Priority to US12/232,445 priority patent/US8163936B2/en
Priority to US12/232,446 priority patent/US8198314B2/en
Priority to US12/232,447 priority patent/US8314257B2/en
Priority to CY20091101153T priority patent/CY1109980T1/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GBGB0324763.2A 2003-10-23 2003-10-23 Use of compounds in therapy Ceased GB0324763D0 (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
GBGB0324763.2A GB0324763D0 (en) 2003-10-23 2003-10-23 Use of compounds in therapy
RU2006109769/04A RU2412934C2 (ru) 2003-10-23 2004-10-19 Применение антагонистов crth2 в терапии
HR20090577T HRP20090577T8 (en) 2003-10-23 2004-10-19 Use of crth2 antagonist compounds in therapy
AT04768943T ATE439129T1 (de) 2003-10-23 2004-10-19 Verwendung von crth2-antagonisten-verbindungen in der therapie
HK07100163.4A HK1093435B (en) 2003-10-23 2004-10-19 Use of crth2 antagonist compounds in therapy
JP2006536158A JP4313819B2 (ja) 2003-10-23 2004-10-19 治療におけるｃｒｔｈ２アンタゴニストの使用
PCT/GB2004/004417 WO2005044260A1 (en) 2003-10-23 2004-10-19 Use of crth2 antagonist compounds in therapy
KR1020067007822A KR20060096145A (ko) 2003-10-23 2004-10-19 티헬퍼세포-2에서 발현되는 유사수용체 유도성 물질의길항제 화합물의 치료용도
CN2004800311128A CN101141956B (zh) 2003-10-23 2004-10-19 Crth2拮抗剂化合物及其制备方法和制药用途
DK04768943T DK1682121T3 (da) 2003-10-23 2004-10-19 Anvendelse af CRTH2-antagonistforbindelser i terapi
UAA200605567A UA86602C2 (ru) 2003-10-23 2004-10-19 Применение соединений антагониста crth2 в терапии
DE602004022579T DE602004022579D1 (de) 2003-10-23 2004-10-19 Verwendung von crth2-antagonisten-verbindungen in der therapie
ES04768943T ES2330113T3 (es) 2003-10-23 2004-10-19 Uso de compuestos antagonistas crth2 en terapia.
SI200431276T SI1682121T1 (sl) 2003-10-23 2004-10-19 Uporaba spojin antagonistov CRTH2 pri terapiji
EP04768943A EP1682121B1 (en) 2003-10-23 2004-10-19 Use of crth2 antagonist compounds in therapy
EP09002934A EP2060258A1 (en) 2003-10-23 2004-10-19 Use of CRTH2 antagonist compounds in therapy
AU2004287245A AU2004287245B2 (en) 2003-10-23 2004-10-19 Use of CRTH2 antagonist compounds in therapy
NZ547319A NZ547319A (en) 2003-10-23 2004-10-19 use of CRTH2 antagonist compounds in therapy
PT04768943T PT1682121E (pt) 2003-10-23 2004-10-19 Utilização de compostos antagonistas de crth2 em terapêutica
CA2543199A CA2543199C (en) 2003-10-23 2004-10-19 Use of crth2 antagonist compounds in therapy
BRPI0415374A BRPI0415374B8 (pt) 2003-10-23 2004-10-19 uso de um composto, composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, e, produto
PL04768943T PL1682121T3 (pl) 2003-10-23 2004-10-19 Zastosowanie związków antagonistów CRTH2 w terapii
US10/972,060 US7582672B2 (en) 2003-10-23 2004-10-22 Compounds for the treatment of CRTH2-mediated diseases and conditions
NO20061456A NO335228B1 (no) 2003-10-23 2006-03-30 Indoleddiksyrederivater og deres anvendelse i behandling og prevensjon av allergisykdommer
IL175085A IL175085A0 (en) 2003-10-23 2006-04-20 Use of crth2 antagonist compounds in therapy
ZA200603235A ZA200603235B (en) 2003-10-23 2006-04-21 Use of CRTH2 antagonist compounds in therapy
US12/232,444 US8163931B2 (en) 2003-10-23 2008-09-17 Treatment of CRTH2-mediated diseases and conditions
US12/232,445 US8163936B2 (en) 2003-10-23 2008-09-17 Treatment of CRTH2-mediated diseases and conditions
US12/232,446 US8198314B2 (en) 2003-10-23 2008-09-17 Treatment of CRTH2-mediated diseases and conditions
US12/232,447 US8314257B2 (en) 2003-10-23 2008-09-17 Treatment of CRTH2-mediated diseases and conditions
CY20091101153T CY1109980T1 (el) 2003-10-23 2009-11-06 Χρηση των ενωσεων ανταγωνιστων toy crth2 στη θεραπεια

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0324763.2A GB0324763D0 (en) 2003-10-23 2003-10-23 Use of compounds in therapy

Publications (1)

Publication Number Publication Date
GB0324763D0 true GB0324763D0 (en) 2003-11-26

Family

ID=29595698

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0324763.2A Ceased GB0324763D0 (en) 2003-10-23 2003-10-23 Use of compounds in therapy

Country Status (25)

Country Link
US (5) US7582672B2 (https=)
EP (2) EP1682121B1 (https=)
JP (1) JP4313819B2 (https=)
KR (1) KR20060096145A (https=)
CN (1) CN101141956B (https=)
AT (1) ATE439129T1 (https=)
AU (1) AU2004287245B2 (https=)
BR (1) BRPI0415374B8 (https=)
CA (1) CA2543199C (https=)
CY (1) CY1109980T1 (https=)
DE (1) DE602004022579D1 (https=)
DK (1) DK1682121T3 (https=)
ES (1) ES2330113T3 (https=)
GB (1) GB0324763D0 (https=)
HR (1) HRP20090577T8 (https=)
IL (1) IL175085A0 (https=)
NO (1) NO335228B1 (https=)
NZ (1) NZ547319A (https=)
PL (1) PL1682121T3 (https=)
PT (1) PT1682121E (https=)
RU (1) RU2412934C2 (https=)
SI (1) SI1682121T1 (https=)
UA (1) UA86602C2 (https=)
WO (1) WO2005044260A1 (https=)
ZA (1) ZA200603235B (https=)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
JP5208510B2 (ja) 2004-11-23 2013-06-12 アストラゼネカ・アクチエボラーグ 呼吸器疾患の処置に有用なフェノキシ酢酸誘導体
ES2369782T3 (es) 2004-12-27 2011-12-05 Actelion Pharmaceuticals Ltd. Derivados de 2,3,4,9-tetrahidro-1h-carbazol como antagonistas del receptor crth2.
GB0504150D0 (en) * 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
GB0512944D0 (en) * 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
EP2397476A3 (en) 2005-07-22 2011-12-28 Shionogi & Co., Ltd. Indole derivative having PGD2 receptor antagonist activity
GB0518783D0 (en) * 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
WO2007044309A2 (en) * 2005-10-05 2007-04-19 Vasix Corporation Device and method for inhibiting age complex formation
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
US8148572B2 (en) 2005-10-06 2012-04-03 Astrazeneca Ab Compounds
ATE545637T1 (de) * 2005-12-15 2012-03-15 Astrazeneca Ab Substituierte diphenylether, -amine, -sulfide und methane zur behandlung von atemwegserkrankungen
GB0605743D0 (en) * 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
EP2037967B1 (en) 2006-06-16 2016-12-07 The Trustees Of The University Of Pennsylvania Prostaglandin d2 receptor antagonists for treating androgenetic alopecia
US7999119B2 (en) 2006-07-22 2011-08-16 Oxagen Limited Compounds having CRTH2 antagonist activity
BRPI0715179A2 (pt) 2006-08-07 2013-06-11 Actelion Pharmaceuticals Ltd composto, composiÇço farmacÊutica e uso de um composto
US20100010034A1 (en) * 2006-12-21 2010-01-14 George Hynd Crth2 antagonists
US20100137300A1 (en) * 2007-03-21 2010-06-03 George Hynd Indolizine Acetic Acid Derivatives as CRTH2 Antagonists
US8273746B2 (en) * 2007-03-23 2012-09-25 The Board Of Regents Of The University Of Texas System Methods involving aldose reductase inhibitors
MX2009010376A (es) * 2007-03-29 2010-01-20 Argenta Oral Therapeutics Ltd Derivados de quinolina como ligandos del receptor crth2.
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
WO2009061730A2 (en) 2007-11-05 2009-05-14 Array Biopharma Inc. 4-heteroaryl-substituted phenoxyphenylacetic acid
US20110124683A1 (en) * 2007-11-13 2011-05-26 Oxagen Limited Use of CRTH2 Antagonist Compounds
GB0722216D0 (en) * 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
GB0722203D0 (en) * 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
PT2229358E (pt) 2007-12-14 2011-06-29 Pulmagen Therapeutics Asthma Ltd Indoles e sua utilização terapêutica
AU2009204700B2 (en) 2008-01-18 2013-07-04 Atopix Therapeutics Limited Compounds having CRTH2 antagonist activity
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
EP2265581A1 (en) * 2008-01-22 2010-12-29 Oxagen Limited Compounds having crth2 antagonist activity
JP2011509991A (ja) * 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
CN101952244B (zh) 2008-02-01 2014-11-05 潘米拉制药公司 前列腺素d2受体的n，n-二取代氨基烷基联苯拮抗剂
EP2257536A4 (en) 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
JP2011513242A (ja) 2008-02-25 2011-04-28 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体アンタゴニスト
WO2009145989A2 (en) 2008-04-02 2009-12-03 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
US8501959B2 (en) 2008-06-24 2013-08-06 Panmira Pharmaceuticals, Llc Cycloalkane[B]indole antagonists of prostaglandin D2 receptors
EP2307362A4 (en) 2008-07-03 2012-05-09 Panmira Pharmaceuticals Llc ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
US20120004233A1 (en) * 2009-01-26 2012-01-05 Amira Pharmaceuticals, Inc Tricyclic compounds as antagonists of prostaglandin d2 receptors
JP2012517405A (ja) * 2009-02-09 2012-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器及び胃腸の疾患の治療のための新規医薬組成物
CN102596193A (zh) * 2009-07-31 2012-07-18 潘米拉制药公司 Dp2受体拮抗的皮肤调配物
KR20120038544A (ko) * 2009-07-31 2012-04-23 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 수용체 길항제의 안과용 약학 조성물
CN102596902A (zh) 2009-08-05 2012-07-18 潘米拉制药公司 Dp2拮抗剂及其用途
CA2782085A1 (en) 2010-01-06 2011-07-14 Panmira Pharmaceuticals, Llc Dp2 antagonist and uses thereof
PT2558447E (pt) 2010-03-22 2014-11-25 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9hcarbazol e o seu uso como moduladores do receptor de prostaglandina d2
US9397745B2 (en) 2010-05-18 2016-07-19 Qualcomm Incorporated Hybrid satellite and mesh network system for aircraft and ship internet service
EP2627178B1 (en) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
EP2661428B1 (en) * 2010-12-23 2017-06-07 Merck Sharp & Dohme Corp. Quinoxalines and aza-quinoxalines as crth2 receptor modulators
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
DK2697223T3 (en) 2011-04-14 2016-09-05 Actelion Pharmaceuticals Ltd 7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor
CN103086943B (zh) * 2011-11-04 2015-04-15 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的吲哚类衍生物
GB201121557D0 (en) 2011-12-15 2012-01-25 Oxagen Ltd Process
EP2790696A1 (en) 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
JP6186933B2 (ja) * 2013-06-21 2017-08-30 富士通株式会社 接合シート及びその製造方法、並びに放熱機構及びその製造方法
GB201322273D0 (en) * 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
AR099767A1 (es) 2014-03-17 2016-08-17 Actelion Pharmaceuticals Ltd Derivados del ácido acético azaindol y su uso como moduladores del receptor de prostaglandina d2
KR20160133536A (ko) 2014-03-18 2016-11-22 액테리온 파마슈티칼 리미티드 아자인돌 아세트산 유도체 및 프로스타글란딘 d2 수용체 조절제로서의 이의 용도
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
TWI695831B (zh) * 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途
ES2991300T3 (es) 2015-02-13 2024-12-03 Inserm Institut Nat De La Sante Et De Larecherche Medicale Antagonistas de PTGDR-1 y/o PTGDR-2 para prevenir y/o tratar lupus eritematoso sistémico
WO2017015418A1 (en) 2015-07-23 2017-01-26 Merck Sharp & Dohme Corp. Genetic markers associated with response to crth2 receptor antagonists
ES2947824T3 (es) 2015-07-30 2023-08-21 Univ Pennsylvania Alelos polimórficos de un solo nucleótido del gen DP-2 humano para la detección de la susceptibilidad a la inhibición del crecimiento del cabello por antagonistas de PGD2
AU2016323262B2 (en) 2015-09-15 2020-11-19 Idorsia Pharmaceuticals Ltd Crystalline forms
US11524958B2 (en) 2016-07-21 2022-12-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compound as CRTH2 inhibitor
AU2017298256B2 (en) * 2016-07-21 2020-11-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indole derivative used as CRTH2 inhibitor
CN108101829B (zh) * 2017-11-19 2020-05-12 华南理工大学 一种吲哚化合物、其制备方法及应用
CA3088917A1 (en) 2018-01-19 2019-07-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal form of indole derivative and preparation method and use thereof
US20220184060A1 (en) 2018-12-27 2022-06-16 Chiesi Farmaceutici S.P.A. Pharmaceutical composition comprising spherical agglomerates of timapiprant
MX2024002745A (es) 2021-09-03 2024-05-20 Shenzhen 01 Life Science And Tech Co Ltd "compuesto de indol, y método de preparacion para el mismo y uso del mismo.

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4324418Y1 (https=) 1965-04-06 1968-10-15
US3489767A (en) * 1966-01-12 1970-01-13 Sumitomo Chemical Co 1-(phenylsulfonyl)-3-indolyl aliphatic acid derivatives
US3557142A (en) * 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
US3577142A (en) * 1969-02-28 1971-05-04 Westinghouse Learning Corp Code translation system
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
GB1407658A (en) 1973-03-06 1975-09-24 Ici Ltd Process for the manufacture of indole derivatives
GB1460348A (en) 1974-02-04 1977-01-06 Ici Ltd Quinazoline derivativesa
DK151884C (da) 1979-03-07 1988-06-13 Pfizer Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
US4363912A (en) 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
WO1993012786A1 (en) 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
US5236945A (en) * 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
GB9122590D0 (en) * 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
GB9317764D0 (en) 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
JP3228381B2 (ja) * 1993-10-29 2001-11-12 ソニー株式会社 Ａｖセレクタ
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
IL117208A0 (en) 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
EP0837052B1 (en) * 1995-06-21 2006-08-23 Shionogi & Co., Ltd. Bicyclic amino derivatives and pgd 2 antagonist containing the same
US6040426A (en) 1996-06-05 2000-03-21 Bml, Inc. Human Th2 specific protein
US6916841B2 (en) 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
EE200000486A (et) 1998-02-25 2002-02-15 Genetics Institute, Inc. Fosfolipaasensüümide inhibiitorid, neid sisaldav farmatseutiline kompositsioon ning meetod põletikulise reaktsiooni raviks imetajal
CA2383983C (en) * 1998-03-31 2009-09-29 The Institutes For Pharmaceutical Discovery, Llc Substituted indolealkanoic acids
GB9825524D0 (en) * 1998-11-20 1999-01-13 Oxford Biomedica Ltd Vector
TNSN99224A1 (fr) 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
JP3486408B2 (ja) 1999-08-23 2004-01-13 株式会社ビー・エム・エル 物質のヒトプロスタグランジンｄ２受容体に対する性質の同定方法
EP1166011A1 (en) 2000-01-14 2002-01-02 Koninklijke Philips Electronics N.V. Display device
AU2001232785A1 (en) 2000-01-14 2001-07-24 The Institutes For Pharmaceutical Discovery, Llc Methods for lowering uric acid levels
US6521659B2 (en) * 2000-03-02 2003-02-18 Institute For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
JP2001247570A (ja) * 2000-03-08 2001-09-11 Japan Tobacco Inc インドール酢酸化合物及びその製造方法
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
AU2003231513A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Pgd2 receptor antagonist
EP2423190A1 (en) * 2002-05-16 2012-02-29 Shionogi&Co., Ltd. Compounds Exhibiting PGD 2 Receptor Antagonism
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
US7364647B2 (en) 2002-07-17 2008-04-29 Eksigent Technologies Llc Laminated flow device
BR0316583A (pt) * 2002-12-10 2005-10-04 Wyeth Corp Derivados de ácido acético 3-alquil e 3-arilalquil 1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
ZA200505523B (en) 2002-12-20 2006-09-27 Amgen Inc Asthma and allergic inflammation modulators
JP4324418B2 (ja) 2003-08-05 2009-09-02 株式会社日立国際電気 基板処理装置および半導体デバイスの製造方法
AU2004283139A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds having CRTH2 antagonist activity
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
GB0504150D0 (en) * 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
WO2006110051A1 (en) * 2005-04-12 2006-10-19 Auckland Uniservices Ltd Pressure assisted thermal sterilisation or pasteurisation method and apparatus
PL65781Y1 (pl) 2005-08-16 2012-02-29 Katarzyna Kawczyńska Wkładka kosmetyczna
GB0605743D0 (en) * 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
US7999119B2 (en) 2006-07-22 2011-08-16 Oxagen Limited Compounds having CRTH2 antagonist activity
US20110124683A1 (en) 2007-11-13 2011-05-26 Oxagen Limited Use of CRTH2 Antagonist Compounds
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
AU2009204700B2 (en) * 2008-01-18 2013-07-04 Atopix Therapeutics Limited Compounds having CRTH2 antagonist activity
JP2011509991A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
EP2265581A1 (en) * 2008-01-22 2010-12-29 Oxagen Limited Compounds having crth2 antagonist activity

Also Published As

Publication number Publication date
US8314257B2 (en) 2012-11-20
PT1682121E (pt) 2009-11-03
US20090018338A1 (en) 2009-01-15
JP2007509114A (ja) 2007-04-12
UA86602C2 (ru) 2009-05-12
HRP20090577T1 (hr) 2009-12-31
US20090018138A1 (en) 2009-01-15
NZ547319A (en) 2009-03-31
RU2412934C2 (ru) 2011-02-27
CN101141956B (zh) 2011-04-20
NO20061456L (no) 2006-07-20
ZA200603235B (en) 2009-03-25
CA2543199A1 (en) 2005-05-19
HK1093435A1 (en) 2007-03-02
BRPI0415374A (pt) 2006-12-12
US20090023788A1 (en) 2009-01-22
AU2004287245A1 (en) 2005-05-19
SI1682121T1 (sl) 2010-01-29
US7582672B2 (en) 2009-09-01
HRP20090577T8 (en) 2009-12-31
CN101141956A (zh) 2008-03-12
DK1682121T3 (da) 2009-10-26
US8163931B2 (en) 2012-04-24
US8198314B2 (en) 2012-06-12
NO335228B1 (no) 2014-10-27
AU2004287245B2 (en) 2009-03-26
ES2330113T3 (es) 2009-12-04
IL175085A0 (en) 2008-04-13
EP1682121B1 (en) 2009-08-12
RU2006109769A (ru) 2007-11-27
ATE439129T1 (de) 2009-08-15
JP4313819B2 (ja) 2009-08-12
EP2060258A1 (en) 2009-05-20
BRPI0415374B8 (pt) 2021-05-25
US20090018139A1 (en) 2009-01-15
CA2543199C (en) 2014-09-23
US8163936B2 (en) 2012-04-24
KR20060096145A (ko) 2006-09-07
PL1682121T3 (pl) 2010-01-29
CY1109980T1 (el) 2014-09-10
BRPI0415374B1 (pt) 2018-10-09
WO2005044260A1 (en) 2005-05-19
EP1682121A1 (en) 2006-07-26
US20050119268A1 (en) 2005-06-02
DE602004022579D1 (de) 2009-09-24

Similar Documents

Publication Publication Date Title
GB0324763D0 (en) Use of compounds in therapy
LUC00155I2 (https=)
WO2008075172A3 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
EG24928A (en) Heterocyclic inhibitors of mek and methods of use thereof
EA200800784A1 (ru) Пиридиновые производные и их применение для лечения психотических расстройств
WO2009047798A3 (en) Acetamide derivatives as glucokinase activators, their process and medicinal applications
NO20090216L (no) Forbindelser med CRTH2 antagonistaktivitet
MY153393A (en) Amino nicotinic and isonicotinic acid derivatives as dhodh as inhibitors
IL176155A0 (en) Polycyclic agents for the treatment of respiratory syncytial virus infections
MX2009011212A (es) Derivados de triazolopiridina carboxamida y triazolopirimidina carboxamida, su preparacion y su aplicacion terapeutica.
NO20071319L (no) Fremgangsmate for fremstilling av isotiazolderivater.
GB0117396D0 (en) Chemical compounds
MXPA04000065A (es) Derivados de aril(o ehteroaril)azolilcarbinoles para el tratamiento de la incontinencia urinaria.
WO2006021655A8 (fr) Dérivés doxopiperidine, leur préparation et leur application en thérapeutique
MX2011012068A (es) Nucleosidos 2'-fluoro arabino y su utilizaicon.
NO20053483L (no) 4-Anilinokinazolinderivater for behandling av unormal cellevekst
ATE546454T1 (de) Pyrrolin-2-on-derivate gegen tumornekrosefaktor freisetzende zellen, herstellungsverfahren und anwendungen davon
NO20005551L (no) 2"-deoksyhygromycinderivater
MXPA04012685A (es) Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina.
PL2177512T3 (pl) Inhibitor wiązania S1P1
UA86040C2 (ru) Производные индола, которые имеют активность антагонистов рецептора crth2
UA104584C2 (ru) Соединения, имеющие активность антагониста crth2
ES2132287T3 (es) Salmicinas, un procedimiento para su preparacion y su uso como producto farmaceutico.
WO2008155818A1 (ja) 頻尿及び尿失禁の予防又は治療剤
SE0402972D0 (sv) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)